open access
The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer
, 1, 23, 34
Affiliations- Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland
- Department of Oncology, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland
- Department of Oncology and Immuno-Oncology, Warmian-Masurian Cancer Center of The Ministry of The Interior and Administration’s Hospital, Olsztyn, Poland
- Department of Radiotherapy, Warmian-Masurian Cancer Center of The Ministry of The Interior and Administration’s Hospital, Olsztyn, Poland
open access
Abstract
Genome instability and mutations are the hallmarks of cancer. Mutations within BRCA genes increase the risk of pancreatic cancer (PC) development. Poly(ADP-ribose) polymerase inhibitors (PARPi) show the synthetic lethality phenomenon in tumoral cells with BRCA mutation and improve outcomes in patients with breast, prostate and ovarian cancer. Olaparib was the first PARPi registered for the patient with metastatic PC with a deleterious or suspected deleterious germline BRCA-mutation. The POLO phase III clinical trial shows that olaparib in PC increases progression-free survival, however it does not prolong the overall survival. Currently, many clinical trials are ongoing to determine the clinical utility of PARPi in monotherapy or polytherapy of PC. The role of PARPi in PC has not been well established and many questions remain unanswered. This review aims to summarise the rationales behind the use of PARPi and current clinical data.
Abstract
Genome instability and mutations are the hallmarks of cancer. Mutations within BRCA genes increase the risk of pancreatic cancer (PC) development. Poly(ADP-ribose) polymerase inhibitors (PARPi) show the synthetic lethality phenomenon in tumoral cells with BRCA mutation and improve outcomes in patients with breast, prostate and ovarian cancer. Olaparib was the first PARPi registered for the patient with metastatic PC with a deleterious or suspected deleterious germline BRCA-mutation. The POLO phase III clinical trial shows that olaparib in PC increases progression-free survival, however it does not prolong the overall survival. Currently, many clinical trials are ongoing to determine the clinical utility of PARPi in monotherapy or polytherapy of PC. The role of PARPi in PC has not been well established and many questions remain unanswered. This review aims to summarise the rationales behind the use of PARPi and current clinical data.
Keywords
PARP inhibitors; olaparib; pancreatic cancer; BRCA mutation
About this articleTitle
The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
34-43
Published online
2022-02-09
Page views
5288
Article views/downloads
365
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2022;72(1):34-43.
Keywords
PARP inhibitors
olaparib
pancreatic cancer
BRCA mutation
Authors
Katarzyna Zubik
Julia Talaśka
Dawid Sigorski
Sergiusz Nawrocki
References (73)- Society. AC. Facts & Figures 2021. American Cancer Society.
- Ducreux M, Cuhna ASa, Caramella C, et al. ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5: v56–v68.
- Springfeld C, Jäger D, Büchler MW, et al. Chemotherapy for pancreatic cancer. Presse Med. 2019; 48(3 Pt 2): e159–e174.
- Piątek M, Nawrocki S. Locally advanced pancreatic cancer — new therapeutic challenges. Nowotwory. Journal of Oncology. 2016; 66(4): 312–316.
- Aguilar-Quesada R, Muñoz-Gámez JA, Martín-Oliva D, et al. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr Med Chem. 2007; 14(11): 1179–1187.
- Martínez-Bosch N, Fernández-Zapico ME, Navarro P, et al. Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases. Am J Pathol. 2016; 186(2): 234–241.
- Sigorski D, Iżycka-Świeszewska E, Bodnar L. Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data. Target Oncol. 2020; 15(6): 709–722.
- Pujade-Lauraine E, Ledermann J, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(9): 1274–1284.
- Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015; 137(3): 386–391.
- Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018; 379(8): 753–763.
- Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020; 21(1): 162–174.
- Doraczyńska-Kowalik A, Janus-Szymańska G, Matkowski R, et al. Genetyka i onkologia (część 2.). Podstawy medycyny personalizowanej w leczeniu raka piersi i raka jajnika. Nowotwory. Journal of Oncology. 2020; 70(5): 187–202.
- Food and Drug Administration. FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma. 2020.
- Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019; 381(4): 317–327.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646–674.
- Goral V. Pancreatic Cancer: Pathogenesis and Diagnosis. Asian Pac J Cancer Prev. 2015; 16(14): 5619–5624.
- Hu C, Hart SN, Polley EC, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 2018; 319(23): 2401–2409.
- Bailey P, Chang DK, Nones K, et al. Australian Pancreatic Cancer Genome Initiative. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592): 47–52.
- Waddell N, Pajic M, Patch AM, et al. Australian Pancreatic Cancer Genome Initiative. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015; 518(7540): 495–501.
- Rondinelli B, Gogola E, Yücel H, et al. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol. 2017; 19(11): 1371–1378.
- Chaudhuri AR, Callen E, Ding X, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016; 535(7612): 382–387.
- Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008; 18(1): 99–113.
- Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010; 11(3): 196–207.
- Lohse I, Kumareswaran R, Cao P, et al. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. PLoS One. 2016; 11(12): e0167272.
- Pilarski R. The Role of Testing in Hereditary Pancreatic and Prostate Cancer Families. Am Soc Clin Oncol Educ Book. 2019; 39: 79–86.
- Yadav S, Kasi PM, Bamlet WR, et al. Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. Clin Cancer Res. 2020; 26(24): 6505–6512.
- Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014; 111(6): 1132–1138.
- Lowery MA, Jordan EJ, Basturk O, et al. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clin Cancer Res. 2017; 23(20): 6094–6100.
- Southey MC, Goldgar DE, Winqvist R, et al. Australian Ovarian Cancer Study Group. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016; 53(12): 800–811.
- Sehdev A, Gbolahan O, Hancock BA, et al. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Clin Cancer Res. 2018; 24(24): 6204–6211.
- Lord C, Ashworth A. BRCAness revisited. Nature Reviews Cancer. 2016; 16(2): 110–120.
- Holter S, Borgida A, Dodd A, et al. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol. 2015; 33(28): 3124–3129.
- Chaffee KG, Oberg AL, McWilliams RR, et al. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med. 2018; 20(1): 119–127.
- Nanda N, Roberts NJ. Serine/Threonine Kinase and its Role in Pancreatic Risk. Genes (Basel). 2020; 11(1).
- Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012; 2(1): 41–46.
- Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015; 148(3): 556–564.
- Mandelker D, Zhang L, Kemel Y, et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017; 318(9): 825–835.
- Ayars M, Eshleman J, Goggins M. Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle. 2017; 16(10): 991–998.
- Wang Y, Kuramitsu Y, Tokuda K, et al. Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. PLoS One. 2014; 9(10): e109076.
- Perkhofer L, Schmitt A, Romero Carrasco MC, et al. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Cancer Res. 2017; 77(20): 5576–5590.
- Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330): 1152–1158.
- McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16): 8109–8115.
- Marteijn JA, Lans H, Vermeulen W, et al. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol. 2014; 15(7): 465–481.
- Li GM. DNA Mismatch Repair and the DNA Damage Response. Encyclopedia of Biological Chemistry. 2013: 51–53.
- Wong W, Raufi AG, Safyan RA, et al. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020; 12: 2731–2742.
- Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res. 2010; 16(18): 4527–4531.
- Lee MV, Katabathina VS, Bowerson ML, et al. BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. Radiographics. 2017; 37(4): 1005–1023.
- Peralta-Leal A, Rodríguez MI, Oliver FJ. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clin Transl Oncol. 2008; 10(6): 318–323.
- Virág L. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. Curr Vasc Pharmacol. 2005; 3(3): 209–214.
- Otto H, Reche PA, Bazan F, et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics. 2005; 6: 139.
- de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A. 1997; 94(14): 7303–7307.
- Martínez-Bosch N, Iglesias M, Munné-Collado J, et al. Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer. J Pathol. 2014; 234(2): 214–227.
- Hou Z, Cui Y, Xing H, et al. Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells. Oncol Lett. 2018; 15(2): 1943–1948.
- Wang M, Wu W, Wu W, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006; 34(21): 6170–6182.
- Pilié PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019; 16(2): 81–104.
- Dedes KJ, Wilkerson PM, Wetterskog D, et al. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011; 10(8): 1192–1199.
- Xu F, Sun Y, Yang SZ, et al. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance. Int J Cancer. 2019; 145(2): 474–483.
- Toma M, Skorski T, Śliwiński T. Synthetic lethality as a functional tool in basic research and in anticancer therapy. Postepy Hig Med Dosw. 2014; 68: 1091–1103.
- Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035): 913–917.
- Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035): 917–921.
- Klauschen F, von Winterfeld M, Stenzinger A, et al. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Histopathology. 2012; 61(3): 409–416.
- Gonçalves A, Finetti P, Sabatier R, et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011; 127(1): 273–281.
- Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015; 33(3): 244–250.
- Golan T, Varadhachary G, Sela T, et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. J Clin Oncol. 2018; 36(4_suppl): 297–297.
- Golan T, Hammel P, Reni M, et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2021; 39(3_suppl): 378–378.
- Reiss KA, Mick R, O'Hara MH, et al. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or . J Clin Oncol. 2021; 39(22): 2497–2505.
- Lowery MA, Kelsen DP, Capanu M, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018; 89: 19–26.
- Matulonis UA, Monk BJ. PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? Ann Oncol. 2017; 28(3): 443–447.
- O'Reilly EM, Lee JW, Lowery MA, et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018; 124(7): 1374–1382.
- O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline Mutation. J Clin Oncol. 2020; 38(13): 1378–1388.
- Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020; 17(2): 108–123.
- Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(4): 439–457.
- Takeuchi S, Doi M, Ikari N, et al. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma. Sci Rep. 2018; 8(1): 8105.